|Bid||59.20 x 800|
|Ask||59.50 x 1100|
|Day's range||58.16 - 59.84|
|52-week range||45.76 - 68.34|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||1.80 (3.09%)|
|Ex-dividend date||01 Oct 2020|
|1y target est||73.50|
Readers hoping to buy Bristol-Myers Squibb Company (NYSE:BMY) for its dividend will need to make their move shortly...
Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial.....
The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.